MedTrace Logo

A Single-arm, Multicenter Study of Automated Axicabtagene Ciloleucel for R/R Large B-cell Lymphoma.

NCT07606937 · Status: RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2026-05-26

No results posted yet for this study

Summary

This study is a single-arm, multicenter, open-label clinical study evaluating the efficacy and safety of axicabtagene ciloleucel injection manufactured by an automated cell preparation process in adult subjects with relapsed or refractory large B-cell lymphoma (r/r LBCL) as second-line therapy.

Conditions

  • Relapsed/Refractory Large B-cell Lymphoma

Interventions

DRUG

FKC876 injection

CD19 CAR-T

Sponsors & Collaborators

  • Shenzhen Fosun Kairos Biotechnology Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Wen Shi · FosunKarios

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-05-01
Primary Completion
2026-11-30
Completion
2026-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07606937 on ClinicalTrials.gov